In 2014, Zhang et al. showed that intraperitoneal injection of an HO-1 inducer-induced IL-10-producing regulatory T cells (Treg) (rather than IBD pathogenic Th17) by inhibiting IL-6/IL-6 receptor signaling, thus ameliorating DSS colitis (64). This evidence concerns the gene IL6 and inflammatory bowel disease.